INS and type 2 diabetes mellitus: The efficacy and safety of tirzepatide have been explored in the phase 3 SURPASS clinical trial program in adults with T2D as monotherapy or in combination with oral medications or basal insulin and compared to placebo or once-weekly semaglutide or basal insulin (degludec, glargine) [66].